OTC Markets OTCQB - Delayed Quote USD

CERo Therapeutics Holdings, Inc. (CERO)

0.0040 -0.0010 (-20.00%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

GlobeNewswire 5d ago

CERO
-20.00%
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

GlobeNewswire 6d ago

CERO
-20.00%
SRXH
CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

GlobeNewswire 6d ago

CERO
-20.00%
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

GlobeNewswire 24d ago

CERO
-20.00%
SRXH
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

GlobeNewswire 2mo ago

CERO
-20.00%
SRXH
Delisting of Securities from The Nasdaq Stock Market

GlobeNewswire 3mo ago

CERO
-20.00%
GTIJF

BHATF
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

GlobeNewswire 6mo ago

CERO
-20.00%
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment

GlobeNewswire 4mo ago

CERO
-20.00%
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

GlobeNewswire 6mo ago

CERO
-20.00%
CEROW
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

GlobeNewswire 5mo ago

CERO
-20.00%
CERo Therapeutics Provides Shareholder Update

GlobeNewswire 7mo ago

CERO
-20.00%
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

GlobeNewswire 8mo ago

CEROW

CERO
-20.00%
SCYX

Performance Overview

Return	CERO	S&P 500 (^GSPC)
YTD	-94.03%	+10.73%
1-Year	-95.79%	+11.11%
3-Year	-100.00%	+81.91%

U.S. markets closed

CERo Therapeutics Holdings, Inc. (CERO)

CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

Delisting of Securities from The Nasdaq Stock Market

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors